Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria

• Published in: Journal of hematology and oncology 2014-03, Vol.7 (1), p.27-27, Article 27
• Main Authors: Araten, David J, Iori, Anna Paola, Brown, Karen, Torelli, Giovanni Fernando, Barberi, Walter, Natalino, Fiammetta, De Propris, Maria Stefania, Girmenia, Corrado, Salvatori, Filippo Maria, Zelig, Orly, Foà, Robin, Luzzatto, Lucio
• Format: Article
• Language: English
• Subjects: Abdomen; Adolescent; Adult; Care and treatment; Embolization, Therapeutic - methods; Female; Health aspects; Hematology; Hemoglobinuria, Paroxysmal - therapy; Humans; Hypersplenism - therapy; Male; Medical treatment; Oncology; Patient outcomes; Short Report; Spleen; Splenic Artery; Thrombocytopenia; Thrombocytopenia - therapy; Transplants & implants; Veins & arteries; Young Adult
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/1756-8722-7-27

PNH is associated with abdominal vein thrombosis, which can cause splenomegaly and hypersplenism. The combination of thrombosis, splenomegaly, and thrombocytopenia (TST) is challenging because anticoagulants are indicated but thrombocytopenia may increase the bleeding risk. Splenectomy could alleviate thrombocytopenia and reduce portal pressure, but it can cause post-operative thromboses and opportunistic infections. We therefore sought to determine whether selective splenic artery embolization (SSAE) is a safe and effective alternative to splenectomy for TST in patients with PNH. Four patients with PNH and TST received successive rounds of SSAE. By targeting distal vessels for occlusion, we aimed to infarct approximately 1/3 of the spleen with each procedure. Three of 4 patients had an improvement in their platelet count, and 3 of 3 had major improvement in abdominal pain/discomfort. The one patient whose platelet count did not respond had developed marrow failure, and she did well with an allo-SCT. Post-procedure pain and fever were common and manageable; only one patient developed a loculated pleural effusion requiring drainage. One patient, who had had only a partial response to eculizumab, responded to SSAE not only with an improved platelet count, but also with an increase in hemoglobin level and decreased transfusion requirement. These data indicate that SSAE can decrease spleen size and reverse hypersplenism, without exposing the patient to the complications of splenectomy. In addition, SSAE probably reduces the uptake of opsonised red cells in patients who have had a limited response to eculizumab, resulting in an improved quality of life for selected patients.